RxDoctor Payments Data

Ladin Yurteri-Kaplan, MD

Urogynecology and Reconstructive Pelvic Surgery · New York, NYNPI 1790014827

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Coloplast at 59.7% of the total. 2025 is the largest year on record at $467, 2.4 times the $192 reported in 2019. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in NY, where the typical reported total is $2,552.

$1,510in general payments, 2019–2025

Across 19 payments — averaging $79.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$901
  • Boston Scientific$313
  • Coopersurgical, Inc.$116
  • Applied Medical Resources Corporation$88
  • Medtronic$74
  • AbbVie$18

What the payments were for

  • Food & beverage$1,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,510 in reported general payments places this provider in the 30th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

See all urogynecology and reconstructive pelvic surgery providers in New York →

Medicare billing

Part B allowed, 2024
$143,951
Medicare patients
281
Services billed
1,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron159$135,441
MyrbetriqMirabegron76$54,399
Estradiol138$10,575
PremarinEstrogens, Conjugated15$6,256
Clobetasol Propionate11$703
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst56$475
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$118
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim36$97
Triamcinolone Acetonide16$79
Oxycodone Hcl48$77
Ibuprofen26$69

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →